INTRODUCTION
One recurrent finding in cancer is the presence of DNA replication stress, which, if persistent, leads to DNA double-strand breaks (DSBs) that initiate genomic rearrangements in cancer cells (1, 2) . In addition to oncogenes, many of the agents used in genotoxic chemotherapy, including antifolates, nucleotide analogs, topoisomerase inhibitors, or platinum derivatives, are potent inducers of replication stress. In mammalian cells, the replication stress response (RSR) is a signaling cascade that initiates with the activation of the kinase ATR and activates the kinase checkpoint kinase 1 (CHK1; encoded by CHEK1) (3, 4) . The presence of DNA replication stress renders cancer cells particularly dependent on a proficient ATR response for survival (5) . Accordingly, studies with a hypomorphic ATR mouse model showed that low levels of ATR are particularly toxic for cells carrying oncogenic mutations (6, 7) . Additionally, ATR or CHK1 inhibitors have exhibited efficacy in hematopoietic tumors, mostly in in vitro settings (6) (7) (8) (9) (10) (11) .
Although persistent replication stress or DNA damage activates the tumor suppressor p53, encoded by TP53, which triggers cell cycle arrest and apoptosis (12) , cell death caused by low ATR activity is not only p53-independent but also enhanced by p53 deficiency (13, 14) . Likewise, the toxicity of chemical inhibitors of ATR is higher in cells lacking p53 (10, 15, 16) . This p53-independent cell killing by ATR inhibitors is linked to their capacity to induce the accumulation of replication stress and premature mitotic entry, activities that are unrelated to p53 functions (17, 18) . Hence, ATR inhibitors offer an alternative for the elimination of p53-deficient tumors.
Previous studies have established that an intact p53 network is a critical determinant of the effectiveness of chemotherapy in acute myeloid leukemia (AML) (19) . MLL (mixed lineage leukemia) refers to chromosomal translocation products involving the gene KMT2A, which encodes histone-lysine N-methyltransferase 2 (20) . In contrast to other oncogenic fusion proteins, cells from AML patients with MLL fusion proteins (AML-MLL) do not mount an effective p53 response and are therefore resistant to current genotoxic treatments (19) . Consistent with this, MLL rearrangements and mutations in TP53 rarely occur together in human AML (21, 22) . Thus, alternative therapies are needed to overcome chemotherapy resistance associated with p53 dysfunction in AML-MLL. In addition to the need of a therapy that works on p53-deficient tumors, several lines of evidence suggested that targeting ATR could be particularly beneficial in AML-MLL. First, reduced amounts of ATR in mouse models inhibited growth of AML driven by the MLL-ENL oncogene, which encodes a fusion of KMT2A and the transcription activator ENL (7) . Second, inhibitors of ATR or its target CHK1 are toxic to human cells and mouse models of several lymphomas and leukemias, including p53-deficient tumors (6-9, 11, 23) . Moreover, the particular efficacy of RSR inhibitors in lymphoid tumors is consistent with a preferential role for the RSR in the untransformed lymphoid compartment, exemplified by the frequent presence of anemia in mice suffering from replication stress (13, (24) (25) (26) (27) damage response (DDR) kinase ATM predisposed primary stem cells infected with retroviruses expressing MLL-AF9, a fusion between KMT2A and the transcription activator AF9, toward differentiation in vitro (28) . On the basis of these data, we predicted that inhibition of ATR or ATM could have potential as a therapy for MLL-associated leukemia. Here, we report the antitumoral effects of ATR or ATM inhibitor monotherapy in an immunocompetent mouse model of AML MLL .
RESULTS

Lymphomas and leukemias have high levels of CHEK1 expression
Because ATR inhibitors are preferentially toxic for cells experiencing replication stress, tumors with high endogenous levels of this stress could be promising targets. We previously showed that increased CHK1 reduces replication stress and improves the survival of cells expressing oncogenes or reprogramming factors (29, 30) . On this basis, we predicted that high CHEK1 expression could be a signature of tumors with high levels of replication stress and, therefore, sensitivity to ATR inhibitors (29) . This hypothesis is supported by work that identified an enrichment of CHEK1 gene amplifications in genomically unstable ovarian cancers, which correlated with an enhanced sensitivity to ATR inhibitors (31) . Hence, CHK1 abundance may provide a biomarker for ATRi sensitivity.
To compare the relative levels of CHEK1 gene expression across different cancer types, we analyzed data from the human Cancer Cell Line Encyclopedia (32) . CHEK1 mRNA was most abundant in Burkitt lymphomas, which we previously showed to be highly dependent on ATR and CHK1 for their survival ( fig. S1 ) (6) . In addition to Burkitt lymphoma, CHEK1 expression was distinctively high in various lymphomas and leukemias ( fig. S1 ). Moreover, studies with hematopoietic tumor cells have shown good efficacy of ATR or CHK1 inhibitors (6) (7) (8) (9) (10) (11) . Overall, these analyses identify distinctively high levels of CHEK1 expression in lymphomas and leukemias, which could be indicative of underlying DNA replication stress. Consistent with our findings, in the companion paper in this issue, David et al. (33) report that CHEK1 expression and CHK1 abundance negatively correlate with prognosis in patients of AML.
AML MLL cells in culture are highly sensitive to ATR inhibitors
From the different kinds of hematopoietic malignancies, we decided to focus on AML carrying MLL translocations for the following reasons. First, mouse genetic studies indicated that ATR abundance is particularly important for the viability of AML cells (7) . Second, ATR-dependent phosphorylation of MLL is involved in the response to replication stress (34) . Third, in vitro experiments showed that ATR inhibitors promote the differentiation of primary stem cells infected with MLL-AF9 (28) . Finally, because of the p53-independent mechanism of cell killing by ATR inhibitors (18) , they could potentially overcome the limitation impinged by p53-deficient responses in MLL-driven AML.
To test the efficacy of ATR inhibition in the treatment of AML in vivo, we used a previously described mouse cell line generated by transforming bone marrow cells with viruses expressing MLL-ENL and N-RAS G12D (AML MLL ). These cells have an activating mutation in NRAS, which is also common in human AML-MLL patients (19) , and these cells recapitulate the deficient p53 signaling and poor responses to conventional chemotherapy that are observed in the clinic with AML-MLL patients (19) . A 1-day treatment of AML MLL cells with the ATR inhibitor AZ20 (35) (hereafter referred to as ATRi) eliminated 75% of the viable cells in culture (Fig. 1A) . The cytotoxicity of ATR inhibitors is mediated by forcing premature mitotic entry from G 2 , the phase during which DSBs are generated (18) . Consistently, exposure to ATRi led to the disappearance of most AML MLL cells from the G 2 phase of the cell cycle (Fig. 1B) . ATRi also resulted in the accumulation of DSBs, as indicated by the phosphorylation of the DDR targets KRAB-associated protein 1 (KAP1), structural maintenance of chromosomes 1 (SMC1), and histone H2AX (Fig. 1C) . Moreover, depletion of p53 with a retrovirus expressing a p53-targeting short hairpin RNA (shRNA) did not rescue the cells from the toxic effects of ATRi (Fig. 1 , D to F).
To determine the mechanism for the sensitivity of AML MLL cells to ATRi, we analyzed the RSR in these cells. Exposure to the ribonucleotide reductase inhibitor hydroxyurea (HU) stimulated the phosphorylation of the ATR targets CHK1 and replication protein A (RPA), ruling out a deficiency in activation and signaling through the replication stress pathway in these cells ( Fig. 2A) . We also compared the response to ATRi in AML MLL cells in an equivalent cell line that was generated by transforming bone marrow cells with viruses expressing an AML1-ETO translocation (AML ETO ). This models a p53-proficient type of AML that has better prognosis than AML patients with the MLL-ENL translocation (19 (Fig. 2D ), exposure to ATRi had a bigger effect in reducing replication fork rates in AML MLL cells, leading to an almost complete impairment of replication fork progression in these cells (Fig. 2D) . In summary, MLL-driven AML cells exhibited an intrinsically higher sensitivity to ATR inhibitors than do AML ETO cells, with ATRi inducing the accumulation of replicative DNA damage, activation of the DDR, and p53-independent death in these cells.
ATR inhibitors show efficacy as single agents in a mouse model of MLL-driven AML
To examine the in vivo efficacy of ATRi, we injected 10 5 AML MLL tumor cells, which also expressed both green fluorescent protein (GFP) and luciferase for tracking, into immunocompetent mice (C57BL/6/BrdCrHsdTyrc). Even in immunocompetent recipients, intravenous injection of AML MLL cells results in a very aggressive form of AML that infiltrates multiple organs and kills mice in a few weeks (19) . In contrast to previous studies (19, 37), we did not irradiate recipient animals before the transplant. Irradiation depletes the bone marrow of the recipient mice, facilitating the expansion of the transplanted tumor. Because the tumor cells proliferated even in the absence of irradiation, we preferred to avoid this treatment to further mimic the normal context of AML. Transplanted mice were treated daily through an oral gavage with a dose of 60 mg/kg of ATRi, and tumor development was followed by monitoring luciferase activity with an in vivo imaging system (IVIS). Finally, to test the efficacy of ATR inhibitors, we used two protocols. In the prevention protocol, mice started receiving treatment on the day of the injection of AML (Fig. 3A) . The treatment of the ATRi Th group started at day 13. Both therapy and prevention groups showed a marked response as measured by IVIS at day 18 (Fig. 3B) . IVIS on isolated organs confirmed that the treatment with ATRi severely limited tumor infiltration to organs, including liver, spleen, and lung (Fig. 3C) . The decreased tumor burden was also evident from visual analysis of spleen sizes (Fig. 3D) . Moreover, and in agreement with the observations made in vitro by exposure of cells to ATR inhibitors (Fig. 2C) , treatment with ATRi led to a widespread accumulation of gH2AX-positive cells in the spleens of the treated mice (Fig. 3E) .
On day 23, we isolated bone marrow from mice of all groups and measured the presence of tumor cells by detection of GFP (Fig. 3F) . GFP-positive cells were undetectable in the prevention group, and the therapy group exhibited a 17-fold decrease in the percentage of GFPpositive AML MLL cells in the bone marrow. Consistent with this, videos of animals recorded on day 25 showed a clear improvement in the overall health of both ATRi-treated groups (movies S1 to S3). Although all animals eventually succumbed to leukemia, both groups showed a significant increase in the median life span (vehicle, 23 days; ATRi Th , 33 days; ATRi PR , 45 days) (Fig. 3A) . Strikingly, at 40 days, all animals from the prevention group were alive, a time at which we decided to stop the treatment to explore potential curative effects of the therapy. Forty percent of these mice survived for more than 50 days, and one was alive for 117 days before succumbing to the disease.
Finally, we measured the efficacy of ATRi in xenografts of the human AML cell line MV4:11, which is also driven by an MLL-AF4 translocation (38) . We subcutaneously implanted MV4:11 cells into the flanks of severe combined immunodeficient (SCID) mice. Treatment with ATRi started when tumors became palpable and was administered daily through oral gavage at 60 mg/kg. ATRi therapy significantly limited the growth of MV4:11 xenografts (Fig. 3G) . In summary, our data showed that ATR inhibition elicits antitumoral responses when used as a single agent in allografts of mouse AML MLL cells and in xenografts of a human AML cell line and provide an example of antitumor activity of this class of drugs in an immunocompetent model of cancer.
ATM inhibitors extend the survival of leukemia-bearing mice
Persistent replication stress leads to the breakage of replication forks and thus to DSBs that triggers an ATM-dependent DDR, suggesting an active role of ATM in limiting the toxicity of replication stress. Consistently, ATM deficiency is lethal in ATR-Seckel mice that accumulate high levels of replication stress (13) . Moreover, previous in vitro data revealed that treatment of primary MLL-AF9 transformed cells with an ATM inhibitor or transformation of ATM knockout cells with MLL-AF9 results in poor growth and increased differentiation of these leukemic cells (28) . To determine whether ATM is required for MLL leukemia in vivo, we first generated wild-type and ATM −/− AML MLL tumors by transforming bone (Fig. 4A) . Thus, even though loss of ATM activity inhibits growth in vitro (28), we found that it did not have a detectable impact on the development of MLL-AF9 leukemia in vivo in primary transplants.
Despite the absence of an impact of ATM deletion, lack of the kinase activity of ATM is not the same as loss of ATM. For example, ATM kinase-inactivating mutations lead to embryonic lethality in mice, whereas ATM knockout mice are viable and show less genome instability than kinase-dead mutants (39, 40) . To determine the effects of ATM inhibition on MLL leukemia, we used the newly developed ATM inhibitor AZD0156 (referred to as ATMi hereafter) (41) (Fig. 4B) .
To determine the efficacy of the ATMi, we repeated the same prevention and therapy protocols that we used to evaluate the ATR inhibitors. We injected AML MLL cells through the tail vein into the mice and treated the mice daily with 20 mg/kg of the ATMi or with the vehicle. In the prevention protocol, treatment started on the day of injection (ATMi Pr ); in the therapy protocol, treatment started when tumors were first detectable by IVIS (ATMi Th ). The untreated cohort behaved similarly to the previously shown experiments, with a median survival of 26 days. As with ATRi, the therapy with ATMi had a notable effect with either protocol, leading to reduced overall luciferase signal measured by IVIS (Fig. 4C) , smaller spleen size (Fig. 4D) , reduced organ infiltration (Fig. 4E) (Fig. 4F) . Videos of mice recorded on day 23 confirmed the improvement in the overall health of ATMi-treated mice (movies S4 to S6).
DISCUSSION
Current treatment of acute pediatric leukemias involves the use of broad-spectrum genotoxic approaches. However, these lines of chemotherapy are largely ineffective for treatment of leukemias that have MLL translocations. In addition, some of these therapies for AML, such as the topoisomerase II inhibitor etoposide, counterproductively promote MLL translocations and therapy-related leukemia (42, 43) . Thus, treatment of this subset of leukemias would benefit from a targeted therapy that exploits a specific vulnerability in the cancer cells.
One such vulnerability is associated with the function of KMT2A, which is the protein encoded in a gene associated with MLL translocation events. KMT2A is a lysine methyltransferase that functions as an epigenetic regulator (20) . Leukemias carrying MLL fusion proteins require few, if any, additional mutations. Rather, fusion proteins induce leukemia by deregulating transcription at MLL fusion protein target genes, such as the HOXA gene cluster and MEIS1 (44, 45) . Abnormal expression of these genes is associated with epigenetic changes, including alteration in DNA and histone methylation. For example, the histone 3 Lys 79 (H3K79) methylase DOT1L is recruited to MLL fusion protein target genes, and this subtype of leukemia depends on DOT1L enzymatic activity (46) . Similarly, MLL leukemias depend on several hematopoietic transcription factors, such as the bromodomain and extraterminal (BET) protein BRD4, to maintain their leukemic stem cell properties (31, 37, 47) . Thus, one therapeutic approach for leukemogenesis resulting from MLL translocation events is to disrupt the MLL target gene expression program with drugs that target epigenetic-modifying enzymes or the products of genes that depend on such modifications (44) . In this context, drugs that inhibit BET, such as the drug JQ1, or DOT1L are currently under clinical investigation.
In addition to lineage-specific transcriptional circuits, our experiments suggested that a second point of vulnerability in MLL-driven AML is the RSR. Whereas we found that the amount of replication stress markers (gH2AX) is not distinctively high in these tumors, we propose that this treated with vehicle (n = 9), ATMi from day 1 (ATMi Pr ; n = 9), or ATMi from day 8 (ATMi Th ; n = 9). Treatment on both groups stopped at day 40. P value was calculated with the Mantel-Cox log-rank test. ***P < 0.001.
is because these cells have increased levels of RSR factors, such as CHK1, which help buffer the levels of replication stress. Accordingly, the accompanying paper from David et al. (33) reveals increased CHK1 levels in cells from human AML MLL patients. We propose that, whereas this increase in RSR factors limits the basal toxicity of replication stress and thus facilitates tumor growth, it also represents a vulnerability because the tumor cells become particularly dependent on a proficient RSR. To what extent MLL translocations are responsible for the replication stress in AML MLL cells, which have other defects such as N-RAS hyperactivity, remains to be established. Despite the hope for new targeted therapies, mechanisms for resistance to inhibitors of BET (31, 48, 49) or ATR (18) have been uncovered. Noteworthy, perturbing the chromatin-related functions of MLL fusion proteins leads to replication stress (34, 50) . In this context, a combination of RSR inhibitors, leading to p53-independent toxicity, and epigenetic inhibitors, which may both interfere with the transcriptional properties of the MLL fusion protein and further increase the levels of replication stress, could help overcome the resistance of MLL-driven AML to chemotherapy.
MATERIALS AND METHODS
Cells and reagents
Mouse AML cells carrying the MLL-ENL translocation (plus IRES-GFP) and oncogenic N-RAS (luciferase-IRES-N-RAS G12D
), referred to in the text as AML MLL , were developed as previously described (19) . The retroviral plasmid with a p53-targeting shRNA was provided by M. Barbacid and transduced using standard protocols. MV4:11 cells were obtained from the American Type Culture Collection. Cells were cultured under standard conditions (5% CO 2 and 20% O 2 ) in RPMI-1640 (EuroClone) medium supplemented with 10% fetal bovine serum (FBS; Sigma-Aldrich) and penicillin/streptomycin (Pen/Strep; Life Technologies) (10 mg/ml). ATRi (AZ20, synthesized by GVK BIO), ATMi (AZD0156, AstraZeneca), and HU (Sigma-Aldrich) were used as indicated.
Flow cytometry
To measure viability, cells were collected, washed once with phosphatebuffered saline (PBS) (pH 7.4), stained in a DAPI solution [DAPI (0.2 mg/ml) in PBS], and analyzed by flow cytometry in a FACSCanto II (BectonDickinson) machine. For cell cycle profiles, cells were collected, washed with PBS, and fixed in suspension in ice-cold 70% (v/v) ethanol in PBS. After washing in PBS, cells were stained in PBS containing propidium iodide (10 mg/ml) and ribonuclease A (0.5 mg/ml) and collected in a BectonDickinson FACSCalibur machine. For DNA content and gH2AX analysis, p-Ser 139 H2AX (Millipore) antibodies were used as previously described (18) . Data were analyzed by FACSDiva (BD Biosciences) and FlowJo (Tree Star) softwares.
Protein extracts and Western blotting
For total protein extract preparation, AML MLL cells were collected upon treatment with ATRi (5 mM for 6 hours) or HU (2 mM for 2 hours), washed once with PBS, and lysed in urea buffer [8 M were used for detection with a LI-COR Odyssey infrared imaging system (LI-COR Biosciences).
Transplantation and in vivo treatment studies
For tumor induction and treatment studies, 10 5 AML MLL cells were transplanted by tail vein injection into 8-to 12-week-old immunocompetent albino recipient mice (C57BL/6/BrdCrHsd-Tyrc). In the case of xenografts, 1.4 × 10 5 MV4:11 cells were injected subcutaneously into the flanks of SCID mice, and tumor growth was measured with a caliper. The mice were treated daily with ATRi (50 mg/kg; dissolved in 10% Nmethyl-2-pyrrolidone/90% polyethylene glycol 300) or ATMi [20 mg/kg; dissolved in 10% dimethyl sulfoxide/90% Captisol (30%)], and the corresponding vehicles by oral gavage. Health status of the treated mice was monitored daily. The mice were maintained at the CNIO under standard housing conditions with free access to chow diet and water, in recommendation of the Federation of European Laboratory Animal Science Association. All mouse work was performed in accordance with the Guidelines for Humane Endpoints for Animals Used in Biomedical Research and under the supervision of the Ethics Committee for Animal Research of the Instituto de Salud Carlos III.
Monitoring of leukemias
To monitor tumor formation, AML MLL transplanted mice were monitored every 3 to 4 days, starting 5 days after the injection of tumor cells, by bioluminescent imaging with an IVIS spectrum imaging system. The mice were intraperitoneally injected with 150 mg/kg of D-luciferin (Perkin-Elmer), anesthetized with isoflurane, and imaged for 30 s after 5 min after luciferin injection. For bioluminescence analysis of organs, the mice were injected with D-luciferin and euthanized by CO 2 , and the organs were collected and imaged for 5 s. To measure the persistence of AML MLL cells, we isolated bone marrow from vehicle-or ATRi-treated animals by flushing femurs and tibias [RPMI-1640 medium supplemented with 10% FBS and Pen/Strep (10 mg/ml)]. Erythrocyte lysis was performed by treating bone marrow cells with a commercial ACK (ammonium-chloride-potassium) red lysis buffer (Lonza) for 5 min at room temperature. Cells were stained with c-KIT APC-H7 antibody (BD Biosciences) and analyzed in FACSCanto II (BD Biosciences; FACSDiva software). Data were analyzed with FlowJo (Tree Star) software.
Histopathology
Spleens were collected from vehicle-and ATRi-treated mice, fixed in formalin, and embedded in paraffin/formalin blocks. Sections and immunohistochemistry staining against gH2AX were performed following standard procedures. Slides were digitalized with Mirax Scan (Zeiss), and gH2AX-positive cells were automatically quantified from digitalized slides with AxioVision 4.6.3 software (Zeiss).
DNA fiber analyses
AML and AML
ETO cells were pulse-labeled with 50 mM chlorodeoxyuridine (CldU) (20 min) followed by 250 mM iododeoxyuridine (IdU) (20 min). Labeled cells were collected, and DNA fibers were spread in buffer containing 0.5% SDS, 200 mM tris (pH 7.4), and 50 mM EDTA. For immunodetection of labeled tracks, fibers were incubated with primary antibodies [for CldU, rat anti-BrdU (bromodeoxyuridine); for IdU, mouse anti-BrdU] for 1 hour at room temperature and developed with the corresponding secondary antibodies for 30 min at room temperature. Mouse anti-single-stranded DNA antibody was used to assess fiber integrity. Slides were examined with a Leica DM6000 B microscope, as described previously (51) . The conversion factor used was 1 mm = 2.59 kb (52) .
SUPPLEMENTARY MATERIALS
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